Patents by Inventor Mark Louis Heiman

Mark Louis Heiman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Growth hormone secretagogues
    Patent number: 6992097
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: January 31, 2006
    Assignee: Eli Lilly and Company
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, Jeffrey Daniel Cohen, James Densmore Copp, Kennan Joseph Fahey, William Harlan Gritton, Louis Nickolaus Jungheim, Joseph Henry Kennedy, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, David Edward Seyler, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Growth Hormone secretagogues
    Publication number: 20040122234
    Abstract: This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.
    Type: Application
    Filed: June 3, 2003
    Publication date: June 24, 2004
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, Jeffrey Daniel Cohen, James Densmore Copp, Kennan Joseph Fahey, William Harlan Gritton, Louis Nickolaus Jungheim, Joseph Henry Kennedy, Charles Willis Lugar, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, David Edward Seyler, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Method for selectively inhibiting ghrelin action
    Publication number: 20030211967
    Abstract: The present invention provides a method selectively inhibiting ghrelin activity to treat a variety of diseases including obesity and related disorders, particularly in individuals who are genetically predisposed. One aspect of the invention comprises administering an agent that effectively neutralizes ghrelin. Another aspect comprises administering a ghrelin receptor (growth hormone secretagogue receptor) antagonist.
    Type: Application
    Filed: October 18, 2002
    Publication date: November 13, 2003
    Inventors: Henry Uhlman Bryant, Mark Louis Heiman
  • Growth hormone secretagogues
    Patent number: 6639076
    Abstract: This invention relates to novel compounds of formula I wherein A, B, D, E, G, J, L, X, V are as defined in the specification, and the compounds are useful in the modulation of endogenous growth hormone levels in a mammal.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: October 28, 2003
    Assignee: Eli Lilly and Company
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, James Densmore Copp, William Harlan Gritton, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Benzofurylpiperazine serotonin agonists
    Patent number: 6638936
    Abstract: The present invention provides serotonergic benzofurans of Formula I: where R is methyl or ethyl, or pharmaceutically acceptable acid addition salts thereof.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: October 28, 2003
    Assignee: Eli Lilly and Company
    Inventors: Karin Briner, Timothy Paul Burkholder, Mark Louis Heiman, David Lloyd Garver Nelson
  • Beta-lipotropin and uses thereof
    Publication number: 20030073621
    Abstract: The invention provides isolated nucleic acids, vectors, transformed host cells, analogs, functional fragments, and fusion proteins, related to beta-lipotropin. Also provided are pharmaceutical compositions comprising beta-lipotropin or fragments and/or analogs thereof, and methods for treating diabetes and complications associated therewith by administration of an effective amount of beta-lipotropin.
    Type: Application
    Filed: April 2, 2001
    Publication date: April 17, 2003
    Inventors: John Edward Hale, Mark Louis Heiman, Brigitte Elisabeth Schoner, Jon Paul Butler, William Francis Heath, Gerald Wayne Becker, Alexander David Varshavsky
  • Beta-lipotropin methods
    Patent number: 6323178
    Abstract: The invention provides isolated nucleic acids, vectors, transformed host cells, analogs, functional fragments, and fusion proteins, related to beta-lipotropin. Also provided are pharmaceutical compositions comprising beta-lipotropin or fragments and/or analogs thereof, and methods for treating diabetes and complications associated therewith by administration of an effective amount of beta-lipotropin.
    Type: Grant
    Filed: December 21, 1998
    Date of Patent: November 27, 2001
    Assignee: Eli Lilly and Company
    Inventors: John Edward Hale, Mark Louis Heiman, Brigitte Elisabeth Schoner, William Francis Heath, Jr.
  • Methods of treating neuropeptide Y-associated conditions
    Patent number: 6221838
    Abstract: This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: April 24, 2001
    Assignee: Eli Lilly and Company
    Inventors: Juliana Maude Bue-Valleskey, Mark Louis Heiman, Thomas Wesley Stephens, Frank C. Tinsley
  • Methods of treating nueropeptide Y-associated conditions
    Patent number: 5972888
    Abstract: This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an obesity protein. This invention also describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: October 26, 1999
    Assignee: Eli Lilly and Company
    Inventors: Juliana Maude Bue-Valleskey, Mark Louis Heiman, Thomas Wesley Stephens, Frank C. Tinsley
  • Method of treating insulin resistance
    Patent number: 5939387
    Abstract: The present invention is in the field of human medicine, particularly in the treatment of Non-insulin Dependent Diabetes Mellitus (NIDDM) and other insulin resistant states such as those associated with obesity and aging. The invention provides a method of treating insulin resistant mammals, which comprises administering to a mammal in need thereof a growth hormone releasing agent.
    Type: Grant
    Filed: September 5, 1996
    Date of Patent: August 17, 1999
    Assignee: Eli Lilly and Company
    Inventors: Carol Lynn Broderick, Richard Dennis DiMarchi, Mark Louis Heiman, Lawrence Edward Stramm